No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection By Ogkologos - June 22, 2026 189 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Rediscovered Drugs Hit Leukemia from Two Different Angles July 21, 2020 Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic December 20, 2022 FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... July 19, 2024 Cancer vaccines – where are we? February 24, 2023 Load more HOT NEWS Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... Identifying Safer Ways to Look for Recurrence After Testicular Cancer Surgery EMA Recommends Granting a Marketing Authorisation for Tepotinib Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in...
